GD Culture Group Ltd
fed844d922682eb2cffc6d6560b157bc5e82c51c
GD Culture Group Ltd completed an acquisition involving Pallas Capital Holding Ltd for an aggregate of 39,189,344 shares of common stock (closed 2025-09-29).
pursuant to which the Company will acquire 100% of the issued and outstanding ordinary shares of the Target from the Sellers (the “Transaction”) in exchange for an aggregate of 39,189,344 shares of common stock, par value $0.0001 per share, of the Company. The Transaction contemplated by the Agreement closed on September 29, 2025. The information disclosed in Item
Leef Brands completes acquisition of Standard Holdings; issues 12.6M shares and $10K cash
This filing
pursuant to which the Company will acquire 100% of the issued and outstanding ordinary shares of the Target from the Sellers (the “Transaction”) in exchange for an aggregate of 39,189,344 shares of common stock, par value $0.0001 per share, of the Company. The Transaction contemplated by the Agreement closed on September 29, 2025. The information disclosed in Item
Comparable filing
the Introductory Note of this Current Report on Form 8-K is incorporated by reference in this Item 2.01. As consideration for the Merger, the Company (a) issued an aggregate of 12,592,960 shares of the Company’s common shares, no par value (“Merger Shares”), to the holders of SHI’s senior preferred stock and (b) paid an aggregate of $10,000.00 in cash to the
Oncotelic completes merger transferring patent portfolio to Lunai for $20M Series B Preferred stock
This filing
pursuant to which the Company will acquire 100% of the issued and outstanding ordinary shares of the Target from the Sellers (the “Transaction”) in exchange for an aggregate of 39,189,344 shares of common stock, par value $0.0001 per share, of the Company. The Transaction contemplated by the Agreement closed on September 29, 2025. The information disclosed in Item
Comparable filing
greement and Plan of Merger (the “Merger Agreement”) with Lunai Bioworks, Inc., a Delaware corporation (“Lunai”), Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of Lunai (“Merger Sub”), Neurobridge IP Holdings
Invech buys sportypick.com sports betting platform for 5M restricted shares of IVHI stock
This filing
pursuant to which the Company will acquire 100% of the issued and outstanding ordinary shares of the Target from the Sellers (the “Transaction”) in exchange for an aggregate of 39,189,344 shares of common stock, par value $0.0001 per share, of the Company. The Transaction contemplated by the Agreement closed on September 29, 2025. The information disclosed in Item
Comparable filing
has agreed to sell and the Company has agreed to purchase the website and total code of the sports betting platform www.sportypick.com owned by Day (the “Assets”) in exchange for 5,000,000 restricted shares of common stock of the Company (the “Shares”). The foregoing information is a summary of the APA involved in the transaction described above, is not complete,
VisionWave acquires xClibre AI video IP for 7M shares + $6M note; $60M valuation
This filing
pursuant to which the Company will acquire 100% of the issued and outstanding ordinary shares of the Target from the Sellers (the “Transaction”) in exchange for an aggregate of 39,189,344 shares of common stock, par value $0.0001 per share, of the Company. The Transaction contemplated by the Agreement closed on September 29, 2025. The information disclosed in Item
Comparable filing
Company”) entered into an Asset Purchase Agreement (the “Agreement”) with Dream America Marketing Services, Ltda., a Costa Rican company (the “Seller”). Pursuant to the Agreement, the Company agreed to acquire
BiomX acquires ZorroNet, enters AI defense with $1.25M note and stock
This filing
pursuant to which the Company will acquire 100% of the issued and outstanding ordinary shares of the Target from the Sellers (the “Transaction”) in exchange for an aggregate of 39,189,344 shares of common stock, par value $0.0001 per share, of the Company. The Transaction contemplated by the Agreement closed on September 29, 2025. The information disclosed in Item
Comparable filing
active engagements with Elbit Systems Ltd (TASE/Nasdaq: ESLT) and other top Israel’s preeminent defense prime contractors. As consideration, the Company issued to Water IO: (i) 1,300,000 shares of common stock ; and (ii) a non-convertible promissory note in the amount of $1,250,000 , bearing interest at the short-term applicable federal rate, payable July 7, 2026.
Acquired Teyamé 360 reports FY2025 revenue $17.2M, net profit $1.1M
This filing
pursuant to which the Company will acquire 100% of the issued and outstanding ordinary shares of the Target from the Sellers (the “Transaction”) in exchange for an aggregate of 39,189,344 shares of common stock, par value $0.0001 per share, of the Company. The Transaction contemplated by the Agreement closed on September 29, 2025. The information disclosed in Item
Comparable filing
relating to the acquisition by Teyame AI Holdings Inc., the Company’s wholly owned subsidiary, of all of the outstanding equity interests of Teyamé 360 S.L. and Datono Mediación S.L. pursuant to that certain Share Purchase Agreement, dated January 22, 2026
Abundia Global Impact acquires RPD Technologies for $4.04M via convertible note
This filing
pursuant to which the Company will acquire 100% of the issued and outstanding ordinary shares of the Target from the Sellers (the “Transaction”) in exchange for an aggregate of 39,189,344 shares of common stock, par value $0.0001 per share, of the Company. The Transaction contemplated by the Agreement closed on September 29, 2025. The information disclosed in Item
Comparable filing
the Company acquired (the “Acquisition”) all the issued and outstanding membership interests of RPD (the “Membership Interests”) from Abundia Financial for the consideration of $4,040,000, payable in the form of a senior secured convertible cote (the “Convertible Note”). The Convertible Note is secured, and in connection therewith, the parties entered into a
Community Health Systems closes sale of four Arkansas hospitals for $110M cash to Freeman Health System
This filing
pursuant to which the Company will acquire 100% of the issued and outstanding ordinary shares of the Target from the Sellers (the “Transaction”) in exchange for an aggregate of 39,189,344 shares of common stock, par value $0.0001 per share, of the Company. The Transaction contemplated by the Agreement closed on September 29, 2025. The information disclosed in Item
Comparable filing
the closing of the Transaction, after giving effect to estimated working capital, the assumption of finance leases by the Purchaser and before certain transaction expenses, was $110 million in cash (subject to a post-closing working capital adjustment). The foregoing summary of the Transaction and the terms and conditions of the Purchase Agreement is subject to, and
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.